Sanofi SA (NYSE:SNY) was the recipient of some unusual options trading on Wednesday. Stock traders bought 12,970 call options on the stock. This represents an increase of 2,258% compared to the average daily volume of 550 call options.
Shares of NYSE SNY opened at $46.08 on Friday. The stock has a market capitalization of $116.19 billion, a PE ratio of 14.72, a P/E/G ratio of 2.41 and a beta of 0.67. The company has a quick ratio of 0.85, a current ratio of 1.22 and a debt-to-equity ratio of 0.40. The firm has a fifty day moving average of $46.16 and a 200-day moving average of $43.91. Sanofi has a 52-week low of $40.00 and a 52-week high of $47.47.
Sanofi (NYSE:SNY) last issued its earnings results on Thursday, October 31st. The company reported $1.07 earnings per share for the quarter, topping the consensus estimate of $0.96 by $0.11. Sanofi had a return on equity of 18.18% and a net margin of 12.20%. The business had revenue of $10.56 billion for the quarter, compared to analyst estimates of $10.62 billion. Equities research analysts expect that Sanofi will post 3.1 EPS for the current fiscal year.
Several analysts have commented on SNY shares. JPMorgan Chase & Co. restated a “neutral” rating on shares of Sanofi in a report on Monday, October 14th. UBS Group raised shares of Sanofi from a “neutral” rating to a “buy” rating in a research note on Wednesday, August 14th. Argus reiterated a “buy” rating and set a $52.00 price objective (up from $50.00) on shares of Sanofi in a report on Wednesday, November 13th. Morgan Stanley raised shares of Sanofi from an “equal” rating to a “weight” rating in a research report on Friday, September 20th. Finally, Sanford C. Bernstein began coverage on shares of Sanofi in a report on Tuesday, September 3rd. They issued an “outperform” rating and a $52.00 target price for the company. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $50.33.
In related news, major shareholder Sanofi sold 172,904 shares of the stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $281.15, for a total transaction of $48,611,959.60. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 1.00% of the company’s stock.
A number of large investors have recently made changes to their positions in the business. Ibex Wealth Advisors purchased a new stake in shares of Sanofi during the 2nd quarter worth about $25,000. Heritage Wealth Advisors raised its holdings in Sanofi by 141.2% in the second quarter. Heritage Wealth Advisors now owns 603 shares of the company’s stock valued at $26,000 after buying an additional 353 shares during the period. Prestige Wealth Management Group LLC acquired a new position in Sanofi during the second quarter valued at approximately $37,000. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA acquired a new position in Sanofi during the third quarter valued at approximately $37,000. Finally, Stonebridge Capital Advisors LLC purchased a new stake in Sanofi during the second quarter worth approximately $41,000. Institutional investors own 7.04% of the company’s stock.
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
Read More: Analyst Ratings
Receive News & Ratings for Sanofi Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Sanofi and related companies with MarketBeat.com’s FREE daily email newsletter.